Phase II study of capecitabine (X) plus docetaxel (T) as neoadjuvant treatment in patients (pts) with locally advanced breast cancer (LABC) including biological correlates.

被引：0
|
作者：
Bellet, M.
Muñoz, M.
Bellosillo, B.
Corominas, J.
Pena, T.
Suárez, M.
Maristany, M.
Perich, J.
Tusquets, I.
Fabregat, X.
机构：
[1] Hosp del Mar, Barcelona, Spain
[2] Hosp Clin Barcelona, Barcelona, Spain
[3] Roche Farma, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：43S / 43S
页数：1
相关论文
共 50 条
  • [41] Phase II study of neoadjuvant treatment with docetaxel, capecitabine, and trastuzumab in HER-2-positive locally advanced or inflammatory breast cancer: TXH trial
    Manga, G. Perez
    Khosravi-Shahi, P.
    Peron, Y. Izarzugaza
    Lovelle, A. Soria
    del Val, R. Gonzalez
    Plaza, M. Palomero
    Martinez, M. Riesco
    Gilarranz, Y. Jerez
    Alfonso, J. Adeva
    Alonso, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Neoadjuvant docetaxel and capecitabine in patients with high risk/locally advanced prostate cancer: Preliminary results of a phase II study.
    Friedman, JD
    Vaishampayan, U
    Montie, J
    Shah, R
    Sarkar, F
    Smith, D
    Hussain, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 438S - 438S
  • [43] A phase I/II study of imatinib and docetaxel as neoadjuvant therapy in locally advanced breast cancer
    Haley, B. B.
    Ashfaq, R.
    DeHaas, M.
    Ramaswami, A.
    Sikder, K.
    Tripathy, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Clinical Advantages of Neoadjuvant Docetaxel (T) and Carboplatin (C) ± Trastuzumab (H) in Locally Advanced Breast Cancer (LABC)
    Chang, H. R.
    Glaspy, J.
    Gornbein, J.
    Kass, F. C.
    Allison, M. A.
    Chung, D. U.
    CANCER RESEARCH, 2009, 69 (24) : 571S - 571S
  • [45] A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer
    Velenik, V.
    Ocvirk, J.
    Oblak, I.
    Anderluh, F.
    EJSO, 2010, 36 (03): : 244 - 250
  • [46] Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast - A single-center, phase II study
    de Matteis, A
    Nuzzo, F
    D'Aiuto, G
    Labonia, V
    Landi, G
    Rossi, E
    Mastro, AA
    Botti, G
    De Maio, E
    Perrone, F
    CANCER, 2002, 94 (04) : 895 - 901
  • [47] A Phase II Trial of Neoadjuvant Gemcitabine, Epirubicin, and Docetaxel as Primary Treatment of Patients With Locally Advanced or Inflammatory Breast Cancer
    Yardley, Denise A.
    Peacock, Nancy W.
    Dickson, Natalie R.
    White, Melissa B.
    Vazquez, Elizabeth R.
    Foust, John T.
    Grapski, Richard
    Hendricks, Linda K.
    Scott, William L.
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2010, 10 (03) : 217 - 223
  • [48] Phase II study of capecitabine and radiotherapy (RT) plus concomitant boost in patients (pts) with locally advanced rectal cancer (LARC).
    Shi, GG
    Lin, E
    Eng, C
    Delcos, M
    Crane, C
    Amos, CB
    Brown, T
    Abbruzzese, JL
    Skibber, J
    Janjan, N
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 312S - 312S
  • [49] Sequential doxorubicine (DOX) and docetaxel (DOC) as neoadjuvant chemotherapy in locally advanced breast cancer (LABC): A pilot study
    Wynendaele, W
    Paridaens, R
    Christiaens, MR
    Van den Bogaert, W
    van Oosterom, AT
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S15 - S15
  • [50] A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer
    Villman, Kenneth
    Ohd, John F.
    Lidbrink, Elisabet
    Malmberg, Lena
    Lindh, Birgitta
    Blomqvist, Carl
    Nordgren, Hans
    Bergh, Jonas
    Bergstrom, Daniel
    Ahlgren, Johan
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (07) : 1153 - 1160
12345